UNASSIGNED: 5098 Background: There are few chemotherapy options for advanced @entity1204 . @entity136 is active in several gynecologic @entity5 including @entity43 , cervical @entity5 ; and has commonly been used in an off-label setting for treatment of advanced @entity1204 , despite a lack of published data showing efficacy. We performed a retrospective review to determine the progression free survival (PFS) and response rate (RR) of @entity1204 @entity1 treated with @entity136 at Memorial Sloan-Kettering Cancer Center (MSKCC). METHODS: Eligible @entity1 had histologically confirmed advanced (stage IV or recurrent) @entity1204 that was treated with @entity136 at MSKCC between 1999 and 2009. Response to therapy was determined by review of CT imaging by RECIST 1.1 criteria. RESULTS: There were 68 @entity1 identified who received @entity136 for advanced @entity1204 between 1999 and 2009; 22 @entity1 were excluded due to lack of available imaging. The median age of the 46 @entity1 included in the analysis was 66 years (range, 52-87). All @entity1 were previously treated with chemotherapy, the median number of prior lines of chemotherapy was 2 (range, 1-8). The median dose of @entity136 administered was 800mg/m(2) infused on day 1 and 8 of a 21 day cycle. The predominant histology was endometrioid (48%, n=22) followed by papillary serous (35%, n=16), clear cell (15%, n=7) and undifferentiated (2%, n=1). The overall RR was 10.9%; 4 @entity1 (9%) achieved a partial response (PR) and 1 @entity1 (2%) achieved a PR that became a complete response after surgical removal of a site of @entity66 . Thirteen @entity1 (28%) displayed @entity66 ( @entity66 ) lasting at least 3 months. Of note, 5 of the 7 (71%) @entity1 with clear cell histology displayed @entity66 or PR (n=5).The median PFS was 3.0 months (95% CI, 2.07 to 3.32). Non-hematologic grade 3 and 4 @entity137 were rare. Ten @entity1 (22%) were treated with @entity1261 ( @entity1261 ) during treatment. CONCLUSIONS: In a mixed population of @entity1 with previously treated advanced @entity1204 , @entity136 was well tolerated and showed modest activity. @entity1 with clear cell histology appeared to have greater likelihood of benefit.

@entity136 for advanced XXXX ( @entity1204 ): A review of the MSKCC experience.

@entity1204 :: ('MESH:D016889', 'Disease') :: ['EMC'] @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities'] @entity66 :: ('MESH:D004194', 'Disease') :: ['residual disease', 'stable disease', 'SD'] @entity1261 :: ('1440', 'Gene') :: ['G-CSF', 'granulocyte-colony stimulating factor'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer and uterine leiomyosarcoma', 'malignancies'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['Gemcitabine', 'gemcitabine']
@entity1204 :: (MESH:D016889,Disease) :: ['endometrial carcinoma']
